Table 1. Baseline demographic and clinical characteristics of patients stratified by treatment strategies after TKI resistance (n=144).
| Characteristics | Total (n=144) | Chemo + IO (n=44) | Chemo + antiangiogenesis (n=100) | P value |
|---|---|---|---|---|
| Age, years, median [range] | 61 [19–76] | 63.5 [19–76] | 58.5 [36–75] | 0.001 |
| Gender, n (%) | 0.421 | |||
| Male | 68 (47.2) | 23 (52.3) | 45 (45.0) | |
| Female | 76 (52.8) | 21 (47.7) | 55 (55.0) | |
| Smoking status, n (%) | 0.554 | |||
| Current/former | 34 (23.6) | 9 (20.5) | 25 (25.0) | |
| Never | 110 (76.4) | 35 (79.5) | 75 (75.0) | |
| EGFR subtypes, n (%) | 0.229 | |||
| 19Del | 77 (53.5) | 22 (50.0) | 55 (55.0) | |
| L858R | 51 (35.4) | 20 (45.5) | 31 (31.0) | |
| Rare mutationsa | 13 (9.0) | 2 (4.5) | 11 (11.0) | |
| Unknown | 3 (2.1) | 0 (0) | 3 (3.0) | |
| PD-L1 status, n (%) | 0.604 | |||
| ≥1% | 6 (4.2) | 3 (6.8) | 3 (3.0) | |
| <1% | 6 (4.2) | 2 (4.5) | 4 (4.0) | |
| Not examined | 132 (91.7) | 39 (88.6) | 93 (93.0) | |
| No. of metastatic sites, n (%) | 0.069 | |||
| 0–1 | 71 (49.3) | 28 (63.6) | 43 (43.0) | |
| 2 | 44 (30.6) | 9 (20.5) | 35 (35.0) | |
| ≥3 | 29 (20.1) | 7 (15.9) | 22 (22.0) | |
| Specific metastasis sites, n (%) | ||||
| Brain | 22 (15.3) | 6 (13.6) | 16 (16.0) | 0.716 |
| Liver | 10 (6.9) | 3 (6.8) | 7 (7.0) | 1.000 |
| Bone | 57 (39.6) | 17 (38.6) | 40 (40.0) | 0.878 |
| Lines of therapy, n (%) | 0.937 | |||
| 2 | 76 (52.8) | 24 (54.5) | 52 (52.0) | |
| 3 | 49 (34.0) | 15 (34.1) | 34 (34.0) | |
| ≥4 | 19 (13.2) | 5 (11.4) | 14 (14.0) |
a, rare mutations include four L861Q, three G719X, two Ex20ins, two L858R and EX20ins co-mutations, one L858R and S768I co-mutation, one L858R and L861Q co-mutation. TKIs, tyrosine kinase inhibitors; IO, immunotherapy; EGFR, epidermal growth factor receptor; PD-L1, programmed cell death ligand 1.